A Randomized, Double-blind, Three-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics, Safety, and Immunogenicity of M834 (Abatacept Biosimilar Candidate), US-Sourced Orencia®, and European Union (EU)-Sourced Orencia® in Normal Healthy Volunteers
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 24 May 2017
At a glance
- Drugs Abatacept (Primary)
- Indications Autoimmune disorders; Inflammation
- Focus Pharmacokinetics
- Sponsors Momenta Pharmaceuticals
- 19 May 2017 Planned End Date changed from 1 Jun 2017 to 1 Jul 2017.
- 19 May 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jul 2017.
- 02 May 2017 Status changed from recruiting to active, no longer recruiting, according to a Momenta Pharmaceuticals media release